Claims:

1. Use of a pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating epilepsy, tonic clonic seizures and/or absence seizures, wherein the pharmaceutical composition is to be administered with a pharmaceutical composition comprising a second active ingredient selected from the group consisting of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, (S)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, wherein the second active ingredient is 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, or a pharmaceutically acceptable salt thereof.

3. The use according to claim 1, wherein the second active ingredient is selected from the group consisting of (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide and 2-propylpentanoic acid; or a pharmaceutically acceptable salt thereof.

4. The use according to claim 1, wherein the second active ingredient is (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide or a pharmaceutically acceptable salt thereof.

5. The use according to claim 1, wherein the second active ingredient is 2-propylpentanoic acid or a pharmaceutically acceptable salt thereof.

6. The use according to any one of claims 1 to 5, wherein the N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and the second active ingredient are comprised in a single pharmaceutical composition.

7. The use according to any one of claims 1 to 5, wherein the N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and the second active ingredient are comprised in separated pharmaceutical compositions.

8. The use according to any one of claims 1 to 7, in the manufacture of a medicament for treating epilepsy.

9. The use according to any one of claims 1 to 7 in the manufacture of a medicament for treating tonic clonic and/or absence seizures.

10. Use of a pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient, in the manufacture of a medicament for treating epilepsy, wherein the pharmaceutical composition is to be administered in combination with a second pharmaceutical composition containing, an active ingredient, 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

11. A kit of parts comprising a first pharmaceutical composition comprising, as an active ingredient, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient; and a second pharmaceutical composition comprising an active ingredient selected from the group consisting of, 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

12. Use of a pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating epilepsy, wherein the pharmaceutical composition is to be administered with a pharmaceutical composition comprising an active ingredient selected from the group consisting of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, (S)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, and further wherein at least one of N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, (S)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, is to be administered at an inactive or a partially active dosage compared to the dosage when the agent is administered alone.

13. The use of claim 12, wherein the pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and the pharmaceutical composition comprising an active ingredient selected from the group consisting of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, (S)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, is to be administered sequentially.

14. The use of claim 12, wherein the pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and the pharmaceutical composition comprising an active ingredient selected from the group consisting of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, (S)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, is to be administered simultaneously.